Drug Discovery & DDS– category –
-
Advances in LNP-Mediated Nucleic Acid Delivery to Respiratory & GI Mucosa: AI Integration for Personalized DDS Future
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are rapidly advancing as a versatile platform to overcome delivery barriers for nucleic acids to respiratory and gastrointestinal mucosal sites. LNPs offer tunable physicochemical prop... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission
BioPharma Dive USA Overview Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average bod... -
AI Drug Discovery Reshapes Early Pharma Pipeline: Accelerates Target ID & Hit Generation to De-risk Late-Stage Failures
Converge Bio Unknown Overview AI-driven drug discovery is primarily impacting the early stages of the pharmaceutical pipeline, such as target identification and hit generation, by significantly accelerating processes that traditionally r... -
AI Drug Development Shifts to Clinical Validation Efficiency with Over 170 AI-Designed Molecules in Trials
Biology Digital News Unknown Overview The AI-driven pharmaceutical sector is reorienting its strategy from rapid drug discovery to enhancing clinical validation efficiency and pipeline quality, with over 170 AI-designed molecules now in ... -
AI-Designed Drugs Achieve 80-90% Phase 1 Success in Lung Cancer, Doubling Market Entry Probability
OncLive USA Overview AI-designed drugs are exhibiting remarkably high Phase 1 success rates of 80-90%, potentially doubling the probability of market entry compared to historical benchmarks. In lung cancer, AI tools show early promise ac... -
AI Accelerates Next-Gen Drug Design: From De Novo Protein Creation to Optimized Clinical Trials
SiTech Blog (MIT Technology Review analysis) USA Overview Artificial intelligence is revolutionizing drug discovery by enhancing every stage from protein structure prediction to clinical trial optimization. Generative models like RFdiffu... -
Drug Discovery & DDS Weekly Report July 26, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 🎙 Podcast July 26, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260726.mp3Download View Past Weekly Reports→ -
TIDES USA 2026: Oligonucleotide CMC Innovations Address Manufacturing and Analytical Bottlenecks
Informa Connect USA Overview The TIDES USA 2026 summit focused on oligonucleotide CMC (Chemistry, Manufacturing, and Controls) innovations, discussing crucial process, analytical, and CMC strategies for clinical and commercial success. K...
